Efficacy of argatroban plus alteplase according to time from onset to thrombolysis in acute ischemic stroke: a prespecified post-hoc analysis of the ARAIS trial

Efficacy of argatroban plus alteplase according to time from onset to thrombolysis in acute ischemic stroke: a prespecified post-hoc analysis of the ARAIS trial

BackgroundThe Argatroban Plus Recombinant Tissue-Type Plasminogen Activator for AIS (ARAIS) trial failed to demonstrate the benefit of argatroban in patients diagnosed with acute ischemic stroke who were treated with intravenous alteplase. A post-hoc analysis was conducted to investigate whether the...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: Yu Cui, Er-Qiang Wang, Yi-Han Wang, Hui-Sheng Chen
Format: Artikel
Sprache:Englisch
Veröffentlicht: Frontiers Media S.A. 2025-06-01
Schriftenreihe:Frontiers in Neurology
Schlagworte:
acute ischemic stroke
argatroban
alteplase
OTT
clinical outcomes
Online-Zugang:https://www.frontiersin.org/articles/10.3389/fneur.2025.1582513/full
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:BackgroundThe Argatroban Plus Recombinant Tissue-Type Plasminogen Activator for AIS (ARAIS) trial failed to demonstrate the benefit of argatroban in patients diagnosed with acute ischemic stroke who were treated with intravenous alteplase. A post-hoc analysis was conducted to investigate whether the time from onset to thrombolysis (OTT) affected the outcomes.MethodsThe included patients were classified into two subgroups according to OTT. The primary outcome was an excellent functional outcome at 90 days, defined as a modified Rankin Scale score of 0 or 1. The efficacy of argatroban plus alteplase was investigated in each subgroup compared with alteplase alone.ResultsOverall, 696 patients were included: 452 were assigned to the OTT < 180 min subgroup, and 244 to the OTT ≥ 180 min subgroup. The treatment effect of argatroban plus alteplase was similar to that of alteplase alone in the OTT < 180 min subgroup (adjusted RD [95% CI] = 0.5% [−5.6 to 6.6%]) and OTT ≥ 180 min subgroup (adjusted RD [95% CI] = −1.3% [−9.8 to 7.1%]). No significant interaction between the treatment efficacy and OTT was found (p = 0.75).InterpretationThe prespecified secondary analysis indicated that the efficacy of argatroban plus alteplase did not differ according to OTT in terms of achieving 90-day excellent functional outcomes compared with alteplase alone.Trial registrationClinicalTrials.gov, Identifier: NCT03740958.
ISSN:1664-2295

Ähnliche Einträge